[1]JournalofMedicinalChemistry,2007,vol.50,p.2213-2224
[2]Patent:WO2007/132227,2007,A1
[3]Patent:WO2007/132215,2007,A1
Title: Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles.
Journal: Molecular cancer therapeutics 20170601
Title: Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.
Journal: Investigational new drugs 20130401
Title: Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia.
Journal: Cancer chemotherapy and pharmacology 20120901
Title: Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152).
Journal: Investigational new drugs 20120801
Title: The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.
Journal: British journal of cancer 20120227
Title: Selective aurora kinase inhibitors identified using a taxol-induced checkpoint sensitivity screen.
Journal: ACS chemical biology 20120120
Title: Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.
Journal: Blood 20111201
Title: A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia.
Journal: Leukemia research 20111001
Title: A novel cell-based, high-content assay for phosphorylation of Lats2 by Aurora A.
Journal: Journal of biomolecular screening 20110901
Title: Effects of AZD1152, a selective Aurora B kinase inhibitor, on Burkitt's and Hodgkin's lymphomas.
Journal: Biochemical pharmacology 20110501
Title: Enhanced radiosensitivity of androgen-resistant prostate cancer: AZD1152-mediated Aurora kinase B inhibition.
Journal: Radiation research 20110401
Title: Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110301
Title: Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer.
Journal: British journal of cancer 20110301
Title: Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20110201
Title: AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947.
Journal: Endocrine-related cancer 20110201
Title: Phthalazinone pyrazoles as potent, selective, and orally bioavailable inhibitors of Aurora-A kinase.
Journal: Journal of medicinal chemistry 20110113
Title: P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA.
Journal: BMC cancer 20110101
Title: Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.
Journal: Cancer research 20101201
Title: Aurora kinase inhibitor AZD1152 negatively affects the growth and survival of HTLV-1-infected T lymphocytes in vitro.
Journal: International journal of cancer 20101001
Title: Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor.
Journal: Journal of medicinal chemistry 20100909
Title: Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase.
Journal: Journal of medicinal chemistry 20100527
Title: Aurora kinase inhibitors as anti-cancer therapy.
Journal: Anti-cancer drugs 20100401
Title: The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma.
Journal: Journal of hepatology 20100101
Title: Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer.
Journal: Molecular cancer 20100101
Title: Simultaneous determination of AZD1152 (prodrug) and AZD1152-hydroxyquinazoline pyrazol anilide by reversed phase liquid chromatography.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091101
Title: The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe.
Journal: Cell cycle (Georgetown, Tex.) 20091001
Title: Mitotic drivers--inhibitors of the Aurora B Kinase.
Journal: Cancer metastasis reviews 20090601
Title: Pharmacological inhibition of aurora-A but not aurora-B impairs interphase microtubule dynamics.
Journal: Cell cycle (Georgetown, Tex.) 20090601
Title: AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo.
Journal: Cancer research 20090515
Title: Discovery and development of aurora kinase inhibitors as anticancer agents.
Journal: Journal of medicinal chemistry 20090514
Title: Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1.
Journal: The Biochemical journal 20090513
Title: Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD1152.
Journal: The pharmacogenomics journal 20090401
Title: The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090315
Title: Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152.
Journal: Oncogene 20080522
Title: Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts.
Journal: Haematologica 20080501
Title: Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity.
Journal: Molecular cancer therapeutics 20080301
Title: The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma.
Journal: British journal of haematology 20080201
Title: AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo.
Journal: Blood 20070915
Title: AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20070615
Title: Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase.
Journal: Journal of medicinal chemistry 20070503
Title: Aurora kinases: new targets for cancer therapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20061201
Title: Aurora kinases: shining lights on the therapeutic horizon?
Journal: Oncogene 20050728
Title: Aurora-kinase inhibitors as anticancer agents.
Journal: Nature reviews. Cancer 20041201
Title: Yang J, et al. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood. 2007 Sep
Title: Wilkinson RW, et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res. 2007 Jun 15;13(12):3682-8.
Title: Evans RP, et al. The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Br J Haematol. 2008 Feb;140(3):295-302.
Title: Oke A, et al. AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. Cancer Res. 2009 May 15;69(10):4150-8.
